Effectiveness of Platelet-Rich Plasma Injection in Rotator Cuff Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Lin, Meng-Ting; Wei, Kuo-Chang; Wu, Chueh-Hung

doi:10.3390/diagnostics10040189

Cited by 52 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have indicated little to no pain relief in patients treated for tendinosis pathologies or rotator cuff tears [ 143 , 144 ]. In contrast, several other studies indicated that PRP reduced or even eliminated pain in patients suffering from tendinosis, OA, plantar fasciitis, and other foot and ankle disorders [ 145 , 146 ]. The final platelet concentration and the biocellular composition have been identified as key PRP characteristics that contributed to the consistent analgesic effects observed after PRP applications.…”

Section: Prp Analgesic Effectsmentioning

confidence: 99%

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Everts

Onishi²,

Jayaram

et al. 2020

IJMS

550

319

View full text Add to dashboard Cite

Emerging autologous cellular therapies that utilize platelet-rich plasma (PRP) applications have the potential to play adjunctive roles in a variety of regenerative medicine treatment plans. There is a global unmet need for tissue repair strategies to treat musculoskeletal (MSK) and spinal disorders, osteoarthritis (OA), and patients with chronic complex and recalcitrant wounds. PRP therapy is based on the fact that platelet growth factors (PGFs) support the three phases of wound healing and repair cascade (inflammation, proliferation, remodeling). Many different PRP formulations have been evaluated, originating from human, in vitro, and animal studies. However, recommendations from in vitro and animal research often lead to different clinical outcomes because it is difficult to translate non-clinical study outcomes and methodology recommendations to human clinical treatment protocols. In recent years, progress has been made in understanding PRP technology and the concepts for bioformulation, and new research directives and new indications have been suggested. In this review, we will discuss recent developments regarding PRP preparation and composition regarding platelet dosing, leukocyte activities concerning innate and adaptive immunomodulation, serotonin (5-HT) effects, and pain killing. Furthermore, we discuss PRP mechanisms related to inflammation and angiogenesis in tissue repair and regenerative processes. Lastly, we will review the effect of certain drugs on PRP activity, and the combination of PRP and rehabilitation protocols.

show abstract

Section: Prp Analgesic Effectsmentioning

confidence: 99%

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Everts

Onishi²,

Jayaram

et al. 2020

IJMS

550

319

View full text Add to dashboard Cite

show abstract

“…В целом они демонстрируют значимое (в сравнении с использованием плацебо) уменьшение боли и улучшение функции после курсового применения ГлК и ОТП, особенно при длительном наблюдении (≥6 мес.) [14,15]. В то же время имеются лишь единичные работы, в которых сравнивался терапевтический потенциал этих препаратов при данной патологии [16].…”

Section: Comparison Of the Effectiveness Of Subacromial Administratiounclassified

“…Так, М. Lin и соавт. [14] провели метаанализ 5 РКИ (n=283), в которых лечебное действие ОТП сравнивалось с плацебо (локальное введение физиологического раствора (ФР)), отсутствием лечения и физиотерапией. В трех исследованиях анальгетическое действие активной терапии было более выраженным через 12 нед.…”

Section: терапияunclassified

“…Активная терапия была достоверно более эффективна, чем плацебо, -интенсивность боли составила через 3 мес. 4 Следует отметить, что все исследователи отмечают хорошую переносимость ОТП и ГлК у пациентов с ХБОП и низкую частоту НР при использовании этих препаратов, сопоставимую с соответствующим показателем для плацебо [14,15].…”

Section: терапияunclassified

See 1 more Smart Citation

Comparison of the effectiveness of subacromial administration of platelet-rich plasma and hyaluronic acid in chronic shoulder pain caused by damage to the tendons of the rotator cuff muscles according to a 6-month open clinical study

Нестеренко¹,

Каратеев²,

Макаров³

et al. 2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Local injections of platelet-rich plasma (PRP) and hyaluronic acid (HLA) are considered an effective method for treating chronic shoulder pain (CSP) associated with damage to the tendons of the rotator cuff muscles (RCM).The aim of the study is to compare the effectiveness and safety of local therapy of PRP and HLA in patients with CSP caused by damage to the tendons of the RCM muscles.Materials and methods. The study included 100 patients (54% women and 46% men, average age 51.5±15.1 years) with CSP (persisting for ≥3 months) associated with damage and tendinitis of the supraspinatus, subacute, scapular or small round muscle, confirmed by magnetic resonance imaging or ultrasound (ultrasound). The patients were randomized into two groups of 50 people who were treated with PRP (three injections at 7-day intervals) or HLA (two injections at 7-day intervals). The injections were performed under ultrasound control in the subacromial SAC. The results of the study were evaluated by the dynamics of pain intensity (on a visual analog scale, up to 100 mm) and functional disorders (ASES and CSS indices) after 1, 3 and 6 months.Results. Against the background of the use of PRP and HLA, there was a significant improvement in the condition of patients, while both drugs showed approximately the same effectiveness. The severity of VAS pain decreased from 56.8±15, respectively, after 6 months.5 and 57.6±17.8 mm to 31.8±27.8 and 30.2±26.3 mm, ASES-c 55.8±15.9 and 53.6±14.7 to 74.6±22.4 and 77.3± 22.4, CSS-c 59.2±14.4 and 47.8±16.9 to 69.9±17.3 and 65.6±19.2. the Dynamics of all these indicators in comparison with the baseline level was statistically significant (p<0.001). Number of patients with moderate / mild pain (<40 mm VAS) after 6 months. after the introduction of PRP and HLA was 48% and 60%, requiring regular NSAID intake 30% and 28%, respectively. In all parameters, the difference in the effectiveness of PRP and HLC was not statistically significant (p>0.05). The effectiveness of PRP and HLA (in terms of pain dynamics, ASES, and CSS) was significantly higher in individuals younger than 45 years, compared to older patients. The tolerability of therapy was good – after the introduction of PRP, 40% of patients had a short-term (3–4 days) increase in pain, which did not require the use of additional analgesics or interruption of treatment. No serious adverse reactions were observed when using PRP and HLA.Conclusion. OTP and GLA are effective and safe in the treatment of CSP associated with damage to the tendons of the RCM muscles. The dynamics of pain intensity and functional status after the use of these drugs did not differ. Treatment of PRP and HLA is more effective in people younger than 45 years.

show abstract

“…Especially the numerous positive results from the conservative PRP treatment of joints, justify a continuous investigation of the PRP issue. The overwhelming amount of available data is retrospective; this, however, leads to some meta-analyses on this topic comparing PRP to corticosteroids for mostly orthopedic procedures [ 11 – 13 ], again showing some benefit. Currently, there is no other data, apart from our previous work, towards a PRP application in breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

Eichler

Baucks

Üner

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Introduction. Literature shows platelet-rich plasma (PRP) to improve overall outcomes in orthopedics, dermatology, ophthalmology, gynecology, and plastic surgery. Data on oncological patients is very limited. Only one publication is available on PRP in breast cancer patients. This work evaluated PRP in sentinel node biopsy procedures for breast cancer patients in terms of complication rates and oncological short-term follow-up. Methods. The evaluated PRP was ACP®, i.e., autologous conditioned plasma by Arthrex®. Between 2015 and 2018, 163 patients were offered to receive an ACP®/PRP injection in their lymph node biopsy site. Recruitment resulted in an approximate one-to-one ratio for analysis. Endpoints were major (revision) and minor (seroma, hematoma, and infection) complications rates as well as distant metastases, local recurrence, and overall survival. Median follow-up was 30 months. Results. Complication rates and oncological follow-up showed PRP to be applicable to use in a sentinel node biopsy scenario in breast cancer patients. There were 0 revisions in the ACP®/PRP group and 1.2% revisions in the control group (not significant). Oncological follow-up showed zero (0) distant metastases and local recurrences as well as a 100% 30-month overall survival. Conclusions. This is the first analysis of ACP®/PRP used in breast cancer patients in a sentinel node biopsy setting worldwide. PRP does not seem to increase rates of local recurrence within this 30-month follow-up time frame. Also, trend towards decreasing complication rates could be shown.

show abstract

Effectiveness of Platelet-Rich Plasma Injection in Rotator Cuff Tendinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cited by 52 publications

References 29 publications

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020

Comparison of the effectiveness of subacromial administration of platelet-rich plasma and hyaluronic acid in chronic shoulder pain caused by damage to the tendons of the rotator cuff muscles according to a 6-month open clinical study

Platelet-Rich Plasma (PRP) in Breast Cancer Patients: An Application Analysis of 163 Sentinel Lymph Node Biopsies

Contact Info

Product

Resources

About